Cellino is focused on developing a precision platform that personalizes human cells to create regenerative medicines derived from stem cells. Their approach aims to address significant health challenges, including diseases like Parkinson's, diabetes, and heart disease, by utilizing patient-specific cells that promise safer and more effective treatment options. The company recognizes the limitations of current autologous processes, which are hindered by manual handling, variability, and high operational costs, and seeks to overcome these challenges to improve health outcomes globally.

To achieve its goals, Cellino employs an innovative platform that integrates label-free imaging and high-speed laser editing, enhanced by machine learning technologies. This combination allows for the automation of critical processes such as cell reprogramming, expansion, and differentiation, all within a closed cassette format. This advanced system enables the simultaneous processing of thousands of patient samples in a single facility, significantly increasing scalability and efficiency in the production of personalized regenerative therapies.

United States

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

Cellino

Company Details